Cat. No.: HY-14392

5,6-Dichlorobenzimidazole riboside

Name: 5,6-Dichlorobenzimidazole riboside
Brand: MedChemExpress
SKU: HY-14392
Price: 30.00 USD
Availability: InStock
Rating: 5 (9 reviews)

(Synonyms: DRB)

9 Cited Publications

Customer Review

Based on 9 publication(s) in Google Scholar

5,6-Dichlorobenzimidazole riboside (DRB) is a nucleoside analog that inhibits several carboxyl-terminal domain kinases, including casein kinase II and cell cycle-dependent kinases (CDK). 5, 6-dichlorobenzimidazole riboside has antitumor activity. 5, 6-dichlorobenzimidazole riboside can induce apoptosis.

For research use only. We do not sell to patients.

Purity : 99.89%
CAS No.: 53-85-0
Formula: C₁₂H₁₂Cl₂N₂O₄
Molecular Weight:319.14

Storage:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

5,6-Dichlorobenzimidazole riboside Chemical Structure

CAS No.: 53-85-0

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (9)
Solvent & Solubility
- In Vitro
- In Vivo
Protocols (8)
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All CDK Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
BSC-1	IC₅₀	30 μM Compound: 1f	Antiviral activity against HSV-1 (herpes simplex virus), determined by ELISA in quadruplicate wells using BSC-1 cells Antiviral activity against HSV-1 (herpes simplex virus), determined by ELISA in quadruplicate wells using BSC-1 cells	[PMID: 10882370]
carcinoma cell line	IC₅₀	36 μM Compound: DRB	Compound was tested for inhibition activity of human oral carcinoma cell line (KB ) cells in quadruplicate assay. Compound was tested for inhibition activity of human oral carcinoma cell line (KB ) cells in quadruplicate assay.	[PMID: 10882375]
HCT-116	GI₅₀	25 μM Compound: DRB	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 22225635]
HFF	IC₅₀	24 μM Compound: DRB	Cytotoxicity produced in human foreskin fibroblasts (HFF) cells was estimated by visual scoring of cells unaffected by virus infection in the plaque-reduction assay. Cytotoxicity produced in human foreskin fibroblasts (HFF) cells was estimated by visual scoring of cells unaffected by virus infection in the plaque-reduction assay.	[PMID: 8784445]
HFF	IC₅₀	24 μM Compound: 1f	Visual cytotoxicity against stationary human foreskin fibroblasts (HFF) cells at the time of HCMV plaque enumeration Visual cytotoxicity against stationary human foreskin fibroblasts (HFF) cells at the time of HCMV plaque enumeration	[PMID: 10882370]
HFF	IC₅₀	24 μM Compound: DRB	Compound was tested for visual cytotoxicity on human foreskin fibroblasts (HFF) cells Compound was tested for visual cytotoxicity on human foreskin fibroblasts (HFF) cells	[PMID: 10882375]
HFF	IC₅₀	24 μM Compound: DRB	Compound was evaluated for the visual cytotoxicity scored on HFF cells at time of HCMV plaque enumeration Compound was evaluated for the visual cytotoxicity scored on HFF cells at time of HCMV plaque enumeration	[PMID: 7562945]
HFF	IC₅₀	24 μM Compound: DRB	Tested for the visual cytotoxicity on HFF cells at the time of human cytomegalovirus (HCMV) plaque enumeration Tested for the visual cytotoxicity on HFF cells at the time of human cytomegalovirus (HCMV) plaque enumeration	[PMID: 8071942]
HFF	IC₅₀	24 μM Compound: DRB	Cytotoxicity against human foreskin fibroblasts (HFF) cells Cytotoxicity against human foreskin fibroblasts (HFF) cells	10.1016/S0960-894X(00)80628-9
HFF	IC₅₀	42 μM Compound: 1f	Antiviral activity against towne strain HCMV was determined by plaque reduction assay in duplicate wells using HFF cells Antiviral activity against towne strain HCMV was determined by plaque reduction assay in duplicate wells using HFF cells	[PMID: 10882370]
HFF	IC₅₀	42 μM Compound: DRB	Compound was tested for antiviral activity against human cytomegalovirus (HCMV) by plaque reduction assay using HFF cells Compound was tested for antiviral activity against human cytomegalovirus (HCMV) by plaque reduction assay using HFF cells	[PMID: 10882375]
Huh-7	CC₅₀	40.4 μM Compound: DRB	Cytotoxicity against dual-reporter HCV replicon Huh7 cells by measuring XTT end points after 72 hrs Cytotoxicity against dual-reporter HCV replicon Huh7 cells by measuring XTT end points after 72 hrs	[PMID: 17060518]
Huh-7	CC₅₀	60.7 μM Compound: DRB	Cytotoxicity against dual-reporter HCV replicon Huh7 cells by measuring FLuc reporter activity after 72 hrs Cytotoxicity against dual-reporter HCV replicon Huh7 cells by measuring FLuc reporter activity after 72 hrs	[PMID: 17060518]
Huh-7	EC₅₀	34.1 μM Compound: DRB	Antiviral activity against HCV 1b con1 in dual-reporter HCV replicon Huh7 cells by measuring hRLuc reporter activity after 72 hrs Antiviral activity against HCV 1b con1 in dual-reporter HCV replicon Huh7 cells by measuring hRLuc reporter activity after 72 hrs	[PMID: 17060518]
KB	IC₅₀	100 μM Compound: DRB	The inhibition of KB cell growth was determined The inhibition of KB cell growth was determined	[PMID: 8071942]
KB	IC₅₀	36 μM Compound: 1f	Compound was tested for the inhibition of KB cell growth in quadruplicate wells Compound was tested for the inhibition of KB cell growth in quadruplicate wells	[PMID: 10882370]
KB	IC₅₀	36 μM Compound: DRB	Compound was evaluated for the inhibition of KB cell growth determined in quadruplicate assay Compound was evaluated for the inhibition of KB cell growth determined in quadruplicate assay	[PMID: 7562945]
KB	IC₅₀	36 μM Compound: DRB	Inhibitory activity against growth of human epidermoid oral carcinoma KB cell line Inhibitory activity against growth of human epidermoid oral carcinoma KB cell line	[PMID: 8784445]
LP-1	IC₅₀	29.81 μM Compound: DRB	Cytotoxicity against human LP-1 cells after 72 hrs by alamar blue assay Cytotoxicity against human LP-1 cells after 72 hrs by alamar blue assay	[PMID: 15958589]
MCF7	GI₅₀	36 μM Compound: DRB	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 22225635]
NCI-H929	IC₅₀	20.13 μM Compound: DRB	Cytotoxicity against human NCI-H929 cells after 72 hrs by alamar blue assay Cytotoxicity against human NCI-H929 cells after 72 hrs by alamar blue assay	[PMID: 15958589]
OPM-2	IC₅₀	29.52 μM Compound: DRB	Cytotoxicity against human OPM2 cells after 72 hrs by alamar blue assay Cytotoxicity against human OPM2 cells after 72 hrs by alamar blue assay	[PMID: 15958589]
RPMI-8226	IC₅₀	46.79 μM Compound: DRB	Cytotoxicity against human RPM18226 cells after 72 hrs by alamar blue assay Cytotoxicity against human RPM18226 cells after 72 hrs by alamar blue assay	[PMID: 15958589]
U-266	IC₅₀	41.02 μM Compound: DRB	Cytotoxicity against human U266 cells after 72 hrs by alamar blue assay Cytotoxicity against human U266 cells after 72 hrs by alamar blue assay	[PMID: 15958589]

In Vitro

5,6-Dichlorobenzimidazole riboside (10-80 μg/mL, 72 h) induces p53-dependent apoptosis of human colon cancer cells by blocking RNA synthesis^[5].
5,6-Dichlorobenzimidazole riboside (10-100 μM, 72 h) induces apoptosis of human MCF-7 breast cancer cells by regulating Mcl-1 and BclxL. And activates members of the caspase family in a time - and dose-dependent manner^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Western Blot Analysis^[5]

View Protocol

Cell Line:

LS174T, HT29, SW48
Concentration:

80 μg/mL
Incubation Time:

24 h
Result:

Decreased incorporation of [5,6-3H] uridine and increased level of p53 protein.

Cell Viability Assay^[6]

View Protocol

Cell Line:

MCF-7, T-47D
Concentration:

10, 50, 75,100 μM
Incubation Time:

72 h
Result:

Inhibited cell-growth in a dose-dependent manner.
Resulted in a higher early apoptotic population (5.7 ± 1.1 vs. 2 ± 0.4%) and late apoptotic population (15.9 ± 2.4 vs. 7.7 ± 0.9%) at a concentration of 75 μM.

Western Blot Analysis^[6]

View Protocol

Cell Line:

MCF-7
Concentration:

75 μM
Incubation Time:

0.5, 2, 6, 10 h
Result:

Reduced Mcl-1 protein levels in a time-dependent manner and increased the level of p53 after 6 h.

In Vivo

5,6-Dichlorobenzimidazole riboside (2.0-3.0 mg/0.25 mL water,  intraperitoneally injected twice a day for 5 days) does not inhibit the multiplication of the PR8 strain of influenza virus in mice^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 53-85-0
Appearance Solid
Molecular Weight 319.14
Formula C₁₂H₁₂Cl₂N₂O₄
Color White to off-white
SMILES

OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=CC(Cl)=C(Cl)C=C3N=C2)O1
Synonyms

DRB
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (9)

All RT-PCR

Sort by:

Journal Impact Factor

J Extracell Vesicles

Extracellular vesicles miR-31-5p promotes pancreatic cancer chemoresistance via regulating LATS2-Hippo pathway and promoting SPARC secretion from pancreatic stellate cells. [Abstract]

2024 Aug;13(8):e12488. PMID: 39104296

5,6-Dichlorobenzimidazole riboside purchased from MedChemExpress. Usage Cited in: J Extracell Vesicles. 2024 Aug;13(8):e12488. [Abstract]

PANC-1 EVs upregulated miR-31-5p levels in PSCs even under DRB (5,6-Dichlorobenzimidazole riboside, 10 μM) treatment.
Mol Cell

Endogenous YAP/TAZ partitioning in TEAD condensates orchestrates the Hippo response. [Abstract]

2025 Sep 18;85(18):3425-3442.e10. PMID: 40914169
Mol Cell

Transcription-coupled AID deamination damage depends on ELOF1-associated RNA polymerase II. [Abstract]

2025 Apr 3;85(7):1280-1295.e9. PMID: 40049162
Cell Rep

m6A modification confers thermal vulnerability to HPV E7 oncotranscripts via reverse regulation of its reader protein IGF2BP1 upon heat stress. [Abstract]

2022 Oct 25;41(4):111546. PMID: 36288717

5,6-Dichlorobenzimidazole riboside purchased from MedChemExpress. Usage Cited in: Cell Rep. 2022 Oct 25;41(4):111546. [Abstract]

Transcription inhibitors does not affect heat-mediated E7 mRNA downregulation. CaSki (E) and SiHa (F) cells were pretreated with or without two transcription inhibitors, triptolide and DRB (5,6-Dichlorobenzimidazole riboside) for 60 min, and subjected to HT (42℃, 60 min). Relative expression levels of E7, HSP70 and β-Actin mRNAs were measured by RT-qPCR.
bioRxiv

2025 Oct 11.
bioRxiv

2025 Aug 19.
bioRxiv

2025 May 24.
bioRxiv

2025 April 14.
bioRxiv

2024 July 27.

Solvent & Solubility

In Vitro:

DMF : 100 mg/mL (313.34 mM; Need ultrasonic)

DMSO : 100 mg/mL (313.34 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 7.69 mg/mL (24.10 mM; Need ultrasonic)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.1334 mL

15.6671 mL

31.3342 mL

5 mM

0.6267 mL

3.1334 mL

6.2668 mL

10 mM

0.3133 mL

1.5667 mL

3.1334 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.83 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (7.83 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.83 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocols

All Cell Biology Signal Pathway Related Animals and Diseases

Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zandomeni RO. Kinetics of inhibition by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole on calf thymus casein kinase II. Biochem J. 1989 Sep 1;262(2):469-73. [Content Brief]

[2]. Yankulov K, et al. The transcriptional elongation inhibitor 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole inhibits transcription factor IIH-associated protein kinase. J Biol Chem. 1995 Oct 13;270(41):23922-5. [Content Brief]

[3]. Rickert P, et al. Cyclin C/CDK8 and cyclin H/CDK7/p36 are biochemically distinct CTD kinases. Oncogene. 1999 Jan 28;18(4):1093-102. [Content Brief]

[4]. Schang LM. Cyclin-dependent kinases as cellular targets for antiviral drugs. J Antimicrob Chemother. 2002 Dec;50(6):779-92. [Content Brief]

[5]. te Poele RH, et al. RNA synthesis block by 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) triggers p53-dependent apoptosis in human colon carcinoma cells. Oncogene. 1999 Oct 14;18(42):5765-72. [Content Brief]

[6]. Kuo YH,et al. 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) induces apoptosis in breast cancer cells through inhibiting of Mcl-1 expression. Sci Rep. 2023 Aug 3;13(1):12621 [Content Brief]

[7]. Kissman H M, et al. Synthesis and biological properties of certain 5, 6-dichlorobenzimidazole ribosides. Journal of the American Chemical Society, 1957, 79(5): 1185-1188

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMF / DMSO	1 mM	3.1334 mL	15.6671 mL	31.3342 mL	78.3355 mL
	5 mM	0.6267 mL	3.1334 mL	6.2668 mL	15.6671 mL
	10 mM	0.3133 mL	1.5667 mL	3.1334 mL	7.8336 mL
	15 mM	0.2089 mL	1.0445 mL	2.0889 mL	5.2224 mL
	20 mM	0.1567 mL	0.7834 mL	1.5667 mL	3.9168 mL
DMF / DMSO	25 mM	0.1253 mL	0.6267 mL	1.2534 mL	3.1334 mL
	30 mM	0.1044 mL	0.5222 mL	1.0445 mL	2.6112 mL
	40 mM	0.0783 mL	0.3917 mL	0.7834 mL	1.9584 mL
	50 mM	0.0627 mL	0.3133 mL	0.6267 mL	1.5667 mL
	60 mM	0.0522 mL	0.2611 mL	0.5222 mL	1.3056 mL
	80 mM	0.0392 mL	0.1958 mL	0.3917 mL	0.9792 mL
	100 mM	0.0313 mL	0.1567 mL	0.3133 mL	0.7834 mL

Bioz

Keywords

5,6-Dichlorobenzimidazole riboside

9 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

5,6-Dichlorobenzimidazole riboside

Publications Citing Use of MedChemExpress (MCE) 5,6-Dichlorobenzimidazole riboside

All CDK Isoforms